Is telbivudine effective for the treatment of HBeAg-negative hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

In the HBeAg-negative patients in the phase III GLOBE Trial, the response rates at 1 year were 75% for the telbivudine group and 77% in the 3TC group, whereas 88% of the telbivudine-treated patients and 71% of the lamivudine-treated patients had undetectable HBV DNA. The HBV DNA log reduction was 5.2 (telbivudine group), compared with 4.4 (lamivudine group). [73, 74]

Regarding treatment resistance, a major issue in hepatitis B disease, the reported resistance rates at 1 year were 2.6% for patients on telbivudine and 8.2% for patients on lamivudine. [73, 74]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!